GlaxoSmithKline LLC, Philadelphia, added three new investment options to the lineup of its 401(k) plan.
The company added the BlackRock Russell 2500 Alpha Tilts collective investment trust, American Funds EuroPacific Growth Fund and T. Rowe Price Blue Chip Growth Fund during 2021, according to a comparison of the company's 11-K filing with the SEC on June 28 and last year's filing.
The passive domestic smidcap equity CIT managed by BlackRock, active international equity fund managed by Capital Group and active domestic large-cap growth equity fund managed by T. Rowe Price Group had $446 million, $58 million and $43 million, respectively, in assets in the plan as of Dec. 31, according to the new 11-K filing.
The comparison also shows the plan removed two investment options during 2021.
The plan removed the CRM Small/Mid Cap U.S. Equity strategy, a separately managed account managed by Cramer Rosenthal McGlynn, and the Pzena International Value All Country (ex.-U.S.) CIT during 2021.
As of Dec. 31, 2020, the active international equity CIT managed by Pzena Investment Management had $38 million in assets in the plan, according to the prior 11-K filing. That filing did not disclose the assets in the plan managed by CRM.
The new 11-K filing did not provide reasons for the changes.
As of Dec. 31, the GSK 401(k) Plan had $9.1 billion in assets, according to the new 11-K filing.
GSK spokeswoman Kathleen Quinn could not be immediately reached for further information.
